CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice Report From the Laboratory Science Discussion Group

The Centers for Disease Control and Prevention (CDC) in collaboration with the American Heart Association (AHA) convened a workshop in Atlanta, Ga, on March 14 and 15, 2002, titled, “CDC/AHA Workshop on Inflammatory Markers and Cardiovascular Disease: Applications to Clinical and Public Health Practice,” which was intended to address issues about the appropriate selection and use of inflammatory markers to predict cardiovascular disease (CVD) risk.1 Three concurrent discussion groups on issues related to laboratory, clinical, and population science were held. This report details the discussions and findings of the laboratory science group.

[1]  A. Işık,et al.  Predictive Value of C-reactive Protein in Patients with Unstable Angina Pectoris Undergoing Coronary Artery Stent Implantation , 2004, The Journal of international medical research.

[2]  J. Kaski,et al.  Pregnancy-Associated Plasma Protein A and Its Endogenous Inhibitor, the Proform of Eosinophil Major Basic Protein (proMBP), Are Related to Complex Stenosis Morphology in Patients With Stable Angina Pectoris , 2004, Circulation.

[3]  S. Reis,et al.  Serum Amyloid A as a Predictor of Coronary Artery Disease and Cardiovascular Outcome in Women: The National Heart, Lung, and Blood Institute–Sponsored Women’s Ischemia Syndrome Evaluation (WISE) , 2004, Circulation.

[4]  C. Heeschen,et al.  Prognostic value of placental growth factor in patients with acute chest pain. , 2004, JAMA.

[5]  W. Markiewicz,et al.  Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction. , 2003, The American journal of medicine.

[6]  J. Tijssen,et al.  C-reactive protein and coronary events following percutaneous coronary angioplasty. , 2003, The American journal of medicine.

[7]  J. Tijssen,et al.  The prognostic value of markers of inflammation in patients with troponin T-negative chest pain before discharge from the emergency department. , 2003, The American journal of medicine.

[8]  P. Porela,et al.  Circulating Pregnancy-Associated Plasma Protein A Predicts Outcome in Patients With Acute Coronary Syndrome but No Troponin I Elevation , 2003, Circulation.

[9]  C. Heeschen,et al.  Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes , 2003, Circulation.

[10]  E. Edelman,et al.  Increased Thrombosis After Arterial Injury in Human C-Reactive Protein–Transgenic Mice , 2003, Circulation.

[11]  Nader Rifai,et al.  Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. , 2003, Clinical chemistry.

[12]  R. Califf,et al.  N‐Terminal Pro‐Brain Natriuretic Peptide and Other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients With Unstable Coronary Artery Disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)‐IV Substudy , 2003, Circulation.

[13]  B. Horne,et al.  Do associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency? , 2003, Journal of the American College of Cardiology.

[14]  F. Crea,et al.  Antibody Response to Chlamydial Heat Shock Protein 60 Is Strongly Associated With Acute Coronary Syndromes , 2003, Circulation.

[15]  Sidney C. Smith,et al.  MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION , 2003 .

[16]  D. Mannino,et al.  Population distribution of high-sensitivity C-reactive protein among US men: findings from National Health and Nutrition Examination Survey 1999-2000. , 2003, Clinical chemistry.

[17]  N. Rifai,et al.  Standardization of immunoassays for measurement of high-sensitivity C-reactive protein. Phase I: evaluation of secondary reference materials. , 2003, Clinical chemistry.

[18]  M. Woodward,et al.  Distributions of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe. , 2003, Clinical chemistry.

[19]  R. Califf,et al.  Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. , 2003, Journal of the American College of Cardiology.

[20]  Robert J Glynn,et al.  Alcohol Consumption and Plasma Concentration of C-Reactive Protein , 2003, Circulation.

[21]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[22]  A. M. Johnson,et al.  Commutability of the CRM 470 C-Reactive Protein Value in the Dade Behring N High Sensitivity CRP Assay , 2003, Clinical chemistry and laboratory medicine.

[23]  Subrata Ghosh,et al.  Natalizumab for active Crohn's disease. , 2003, The New England journal of medicine.

[24]  A. Tedgui,et al.  Increased plasma concentrations of interleukin-18 in acute coronary syndromes , 2002, Heart.

[25]  Hyon K. Choi,et al.  Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. , 2002, The American journal of medicine.

[26]  Deepak L. Bhatt,et al.  Need to test the arterial inflammation hypothesis. , 2002, Circulation.

[27]  Paul M. Ridker,et al.  Prospective Study of C-Reactive Protein, Homocysteine, and Plasma Lipid Levels as Predictors of Sudden Cardiac Death , 2002, Circulation.

[28]  Nader Rifai,et al.  Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide , 2002, Circulation.

[29]  S. Marsch,et al.  Inflammation and Long-Term Mortality After Non-ST Elevation Acute Coronary Syndrome Treated With a Very Early Invasive Strategy in 1042 Consecutive Patients , 2002, Circulation.

[30]  B. Horne,et al.  C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. , 2002, Journal of the American College of Cardiology.

[31]  A. Maseri,et al.  Risk of Myocardial Infarction and Angina in Patients With Severe Peripheral Vascular Disease: Predictive Role of C-Reactive Protein , 2002, Circulation.

[32]  A. Abbate,et al.  Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. , 2002, The American journal of cardiology.

[33]  U. Prabhakar,et al.  Simultaneous quantification of proinflammatory cytokines in human plasma using the LabMAP assay. , 2002, Journal of immunological methods.

[34]  M. V. van Dieijen-Visser,et al.  High-sensitivity C-reactive protein methods examined. , 2002, Clinical chemistry.

[35]  P. Ridker,et al.  Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction. , 2002, The American journal of cardiology.

[36]  Cynthia A. Carnes,et al.  C-Reactive Protein Elevation in Patients With Atrial Arrhythmias: Inflammatory Mechanisms and Persistence of Atrial Fibrillation , 2001, Circulation.

[37]  N. Rifai,et al.  Performance characteristics of a point of care C-reactive protein assay. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[38]  O. Wagner,et al.  Evaluation of turbidimetric high-sensitivity C-reactive protein assays for cardiovascular risk estimation. , 2001, Clinical chemistry.

[39]  A. Tedgui,et al.  Expression of Interleukin-18 in Human Atherosclerotic Plaques and Relation to Plaque Instability , 2001, Circulation.

[40]  Deepak L. Bhatt,et al.  Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. , 2001, The American journal of cardiology.

[41]  Deepak L. Bhatt,et al.  Incremental Prognostic Value of Elevated Baseline C-Reactive Protein Among Established Markers of Risk in Percutaneous Coronary Intervention , 2001, Circulation.

[42]  J. Kooner,et al.  C-Reactive Protein, Insulin Resistance, Central Obesity, and Coronary Heart Disease Risk in Indian Asians From the United Kingdom Compared With European Whites , 2001, Circulation.

[43]  K. Kayaba,et al.  Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population : Jichi Medical School Cohort Study. , 2001, American journal of epidemiology.

[44]  R. Pizarro,et al.  C-reactive protein and the stress tests for the risk stratification of patients recovering from unstable angina pectoris. , 2001, The American journal of cardiology.

[45]  P. Crean,et al.  Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules , 2001, Heart.

[46]  S. Grundy,et al.  Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein Levels , 2001, Circulation.

[47]  P. Mills,et al.  The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. , 2001, Journal of the American College of Cardiology.

[48]  V. Rizzello,et al.  Clinical use of C-reactive protein for the prognostic stratification of patients with ischemic heart disease. , 2001, Italian heart journal : official journal of the Italian Federation of Cardiology.

[49]  C. Kluft,et al.  Determination of the habitual low blood level of C-reactive protein in individuals. , 2001, Italian heart journal : official journal of the Italian Federation of Cardiology.

[50]  S. Fichtlscherer,et al.  Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. , 2001, Journal of the American College of Cardiology.

[51]  N Rifai,et al.  Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. , 2001, Clinical chemistry.

[52]  P. Ridker,et al.  Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. , 2001, Clinical chemistry.

[53]  N Rifai,et al.  High Sensitivity Immunoassays for C-Reactive Protein: Promises and Pitfalls , 2001, Clinical chemistry and laboratory medicine.

[54]  N Rifai,et al.  Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. , 2001, Clinical chemistry.

[55]  N Rifai,et al.  Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. , 2001, Clinical chemistry.

[56]  S. Anker,et al.  Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure , 2000, Circulation.

[57]  G. Biondi-Zoccai,et al.  Prognostic value of C-reactive protein in unstable angina. , 2000, Circulation.

[58]  B. Horne,et al.  Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. , 2000, Journal of the American College of Cardiology.

[59]  S. Humphries,et al.  Effects of sample handling on the stability of interleukin 6, tumour necrosis factor-alpha and leptin. , 2000, Cytokine.

[60]  A. Siegbahn,et al.  Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. , 2000, The New England journal of medicine.

[61]  M H Wener,et al.  The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration. , 2000, The Journal of rheumatology.

[62]  P. Gaffney,et al.  A Collaborative Study to Establish the 2nd International Standard for Fibrinogen, Plasma , 2000, Thrombosis and Haemostasis.

[63]  L. Wallentin,et al.  Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial , 2000, The Lancet.

[64]  M. Pfeffer,et al.  Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. , 2000, Circulation.

[65]  C. Heeschen,et al.  Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. , 2000, Journal of the American College of Cardiology.

[66]  N. Rifai,et al.  Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. , 2000, Clinical chemistry.

[67]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[68]  K. Huber,et al.  The association between C‐reactive protein on admission and mortality in patients with acute myocardial infarction , 2000, Journal of internal medicine.

[69]  E. Antman,et al.  Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy. , 2000, Journal of the American College of Cardiology.

[70]  M. Pepys,et al.  C-Reactive Protein and Complement Are Important Mediators of Tissue Damage in Acute Myocardial Infarction , 1999, The Journal of experimental medicine.

[71]  P. Pasqualetti,et al.  Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. , 1999, Journal of the American College of Cardiology.

[72]  M. Leon,et al.  Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae. , 1999, The American journal of cardiology.

[73]  A. Maseri,et al.  Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events. , 1999, The American journal of cardiology.

[74]  C. Held,et al.  Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule-1 among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction. , 1999, European heart journal.

[75]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[76]  E. Carluccio,et al.  C-reactive protein as a marker for cardiac ischemic events in the year after a first, uncomplicated myocardial infarction. , 1999, The American journal of cardiology.

[77]  A. Rebuzzi,et al.  Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. , 1999, Circulation.

[78]  A. Zwinderman,et al.  Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function. , 1999, European heart journal.

[79]  A. Rebuzzi,et al.  Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. , 1999, Circulation.

[80]  A. Döring,et al.  C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. , 1999, Circulation.

[81]  J. Sipe,et al.  Analytical Evaluation of Particle-Enhanced Immunonephelometric Assays for C-Reactive Protein, Serum Amyloid a and Mannose-Binding Protein in Human Serum , 1998, Annals of clinical biochemistry.

[82]  E. Holler,et al.  Validation of an Automated Enzyme Immunoassay for Interleukin-6 for Routine Clinical Use , 1998, Clinical chemistry and laboratory medicine.

[83]  E. Vicaut,et al.  Comparison of the prognostic value of C-reactive protein and troponin I in patients with unstable angina pectoris. , 1998, The American journal of cardiology.

[84]  A. Rebuzzi,et al.  Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. , 1998, The American journal of cardiology.

[85]  M. Pfeffer,et al.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.

[86]  M. Pepys,et al.  Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. , 1998, Clinical chemistry.

[87]  M. Hino,et al.  Problems with assays based on fibrin clot formation principle: analysis of multilaboratory data. , 1998, Osaka city medical journal.

[88]  M. Pepys,et al.  The first international standard for serum amyloid A protein (SAA). Evaluation in an international collaborative study. , 1998, Journal of immunological methods.

[89]  R. De Cristofaro,et al.  Measurement of plasma fibrinogen concentration by the prothrombin-time-derived method: applicability and limitations , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[90]  E. Antman,et al.  C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. , 1998, Journal of the American College of Cardiology.

[91]  Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. , 1998, The New England journal of medicine.

[92]  A. Siegbahn,et al.  Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. , 1997, Circulation.

[93]  D. Ardissino,et al.  C-reactive protein elevation and early outcome in patients with unstable angina pectoris. , 1997, The American journal of cardiology.

[94]  S. Ogawa,et al.  C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. , 1997, Circulation.

[95]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[96]  R. Thorpe,et al.  Implications for the assay and biological activity of interleukin-8: results of a WHO international collaborative study. , 1997, Journal of immunological methods.

[97]  R. Tracy,et al.  Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. , 1997, Clinical chemistry.

[98]  G. Ciliberto,et al.  Elevated levels of interleukin-6 in unstable angina. , 1996, Circulation.

[99]  A. Pasternack,et al.  Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. , 1996, European heart journal.

[100]  J. Cavaillon,et al.  Variable estimates of cytokine levels produced by commercial ELISA kits: results using international cytokine standards. , 1995, Journal of immunological methods.

[101]  G. Assmann,et al.  Fibrinogen and Cardiovascular Risk , 1995, Journal of cardiovascular risk.

[102]  S. Thompson,et al.  Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. , 1995, The New England journal of medicine.

[103]  I. Mackie,et al.  Inaccuracy of the 'derived' fibrinogen measurement. , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[104]  A. Rebuzzi,et al.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.

[105]  W. G. Wood,et al.  The Limitations and Usefulness of C-Reactive Protein and Elastase-α1-Proteinase Inhibitor Complexes as Analytes in the Diagnosis and Follow-up of Sepsis in Newborns and Adults , 1994, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[106]  J. Bienvenu,et al.  Analytical performances of commercial ELISA-kits for IL-2, IL-6 and TNF-alpha. A WHO study. , 1993, European cytokine network.

[107]  C. Fraser,et al.  Biological Variation of Acute Phase Proteins , 1993, Annals of clinical biochemistry.

[108]  S. Poole,et al.  The international standard for interleukin-6. Evaluation in an international collaborative study. , 1993, Journal of immunological methods.

[109]  A. Dobson,et al.  Effect of processing time and storage on fibrinogen content of EDTA plasma assayed by radial immunodiffusion. , 1992, Clinical chemistry.

[110]  S. Ehrmeyer,et al.  The relationship of intralaboratory bias and imprecision on laboratories' ability to meet medical usefulness limits. , 1988, American journal of clinical pathology.

[111]  DifcoTM HycheckTM,et al.  The package insert. , 1969, JAMA.

[112]  Mark Woodward,et al.  Population Distributions of C-reactive Protein in Apparently Healthy Men and Women in the United States : Implication for Clinical Interpretation , 2022 .